Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.

ABSTRACT:

Background

There is no universally accepted treatment for patients with advanced papillary renal cell carcinoma (PRCC). The presence of activating mutations in MET, as well as gain of chromosome 7, where the MET gene is located, are the most common genetic alterations associated with PRCC, leading to the clinical evaluation of MET tyrosine kinase inhibitors (TKIs) in this cancer. However, TKIs targeting MET selectively, as well as multitargeted TKIs with activity against MET demonstrate modest efficacy in PRCC and primary and secondary treatment failure is common; other approaches are urgently needed to improve outcomes in these patients.

Methods

High throughput screening with small molecule libraries identified HSP90 inhibitors as agents of interest based on antitumor activ

SUBMITTER: Pahwa R 

PROVIDER: S-EPMC9235180 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature